GH Research (GHRS) Retained Earnings (2021 - 2025)
GH Research's (GHRS) quarterly Retained Earnings came in at -$154.4 million in Q4 2025, down 45.07% year-on-year from -$281.1 million in Q4 2024, and down 135.82% quarter-over-quarter from $431.1 million in Q3 2025.
GH Research (GHRS) Retained Earnings (2021 - 2025) Analysis & Trends
GH Research's Retained Earnings history runs 5 years deep, the most recent figure standing at -$154.4 million for Q4 2025.
- On a quarterly basis, Retained Earnings fell 45.07% year-over-year to -$154.4 million in Q4 2025; TTM through Dec 2025 was -$154.4 million, a 45.07% decrease from a year earlier, with the FY2025 full-year figure at -$154.4 million, down 45.07% from the prior year.
- Retained Earnings eased to -$154.4 million in Q4 2025 per GHRS's latest filing, from $431.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $431.1 million in Q1 2025 and bottomed at -$154.4 million in Q4 2025.
- The 5-year median for Retained Earnings is $291.4 million (2022), against an average of $199.1 million.
- Across the five-year window, Retained Earnings slumped 167.52% in 2022 and soared 1932.2% in 2023, its largest moves.
- Year by year, Retained Earnings stood at -$16.4 million in 2021, then plunged by 98.45% to -$32.5 million in 2022, then jumped by 997.0% to $291.5 million in 2023, then tumbled by 136.52% to -$106.4 million in 2024, then sank by 45.07% to -$154.4 million in 2025.
- Per Business Quant, the three latest GHRS Retained Earnings figures stand at -$154.4 million (Q4 2025), $431.1 million (Q3 2025), and $431.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | -154.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -154.43 Mn |
| Sep 30, 2025 | 431.06 Mn |
| Jun 30, 2025 | 431.06 Mn |
| Mar 31, 2025 | 431.06 Mn |
| Dec 31, 2024 | -106.45 Mn |
| Sep 30, 2024 | 291.46 Mn |
| Jun 30, 2024 | 291.46 Mn |
| Mar 31, 2024 | 291.46 Mn |
| Dec 31, 2023 | 291.46 Mn |
| Sep 30, 2023 | 291.45 Mn |
| Jun 30, 2023 | 291.45 Mn |
| Mar 31, 2023 | 291.45 Mn |
| Dec 31, 2022 | -32.49 Mn |
| Sep 30, 2022 | -15.91 Mn |
| Jun 30, 2022 | 291.45 Mn |
| Mar 31, 2022 | 291.45 Mn |
| Dec 31, 2021 | -16.37 Mn |
| Sep 30, 2021 | -5.95 Mn |